Return
Titrating Rituximab to Circulating B-Cells Starting From an Ultra-Low Dose for Moderate-to-Severe Pemphigus
R
S
P
X
R
M
DOI:10.1155/dth/1828296.png)
Abstract
En 中文
Rituximab has been proven effective at a dose of 2 g in moderate-to-severe pemphigus by depleting CD20+B-cell; however, studies have found that 100 mg RTX may suffice to fully suppress CD20+B-cell.
Keywords:
B-cell depletion
pemphigus
rituximab
ultra-low dose
Journal
IF:
3.4
Papers:
4.8K
Citations:
7.1K
